Research progress of α1 adrenergic receptor blockers in the treatment of liver cirrhosis

doi:10.3877/cma.j.issn.2095-2015.2022.04.009

Abstract

Abstract:

The need for clinical drug treatment of portal hypertension in liver cirrhosis has not been met. At present, domestic and foreign guidelines mostly recommend non-selective β receptor blockers as standard treatment drugs, but some patients do not have an effective response to such drug therapy. With the further study on the mechanism and pharmacology of portal hypertension in liver cirrhosis, α₁ adrenergic receptor blockers have been found to be of potential therapeutic value. α₁ adrenergic receptor blockers, as drugs with dual effects of intrahepatic sympathetic regulation and vascular activity, can inhibit the process of liver cirrhosis by regulating sympathetic-related mechanisms, and also have a certain effect on reducing portal hypertension, and it has become one of the potential therapeutic drugs for anti-fibrosis and reducing portal hypertension in liver cirrhosis. This article reviews the research progress of α₁ adrenergic receptor blockers in the treatment of liver cirrhosis.

Key words: Liver cirrhosis, Portal hypertension, α₁ receptor blockers

Jinming Yan, Chunqing Zhang. Research progress of α₁ adrenergic receptor blockers in the treatment of liver cirrhosis[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2022, 12(04): 232-235.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhxhbyyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2015.2022.04.009

https://zhxhbyyxzz.cma-cmc.com.cn/EN/Y2022/V12/I04/232

References 40

4	Tsochatzis EA, Bosch J, Burroughs AK. Liver cirrhosis [J]. Lancet, 2014, 383(9930): 1749-1761.
5	de Franchis R, Baveno Ⅵ Faculty. Expanding consensus in portal hypertension: Report of the Baveno Ⅵ Consensus Workshop: Stratifying risk and individualizing care for portal hypertension [J]. J Hepatol, 2015, 63(3): 743-752.
6	Bosch J, Iwakiri Y. The portal hypertension syndrome: etiology, classification, relevance, and animal models [J]. Hepatol Int, 2018, 12(Suppl 1): 1-10.
7	Gana JC, Serrano CA, Ling SC. Angiogenesis and portal-systemic collateralsin portal hypertension [J]. Ann Hepatol, 2016, 15(3): 303-313.
8	European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis [J]. J Hepatol, 2018, 69(2): 406-460.
9	Garcia-Tsao G, Abraldes JG, Berzigotti A, et al. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases [J]. Hepatology, 2017, 65(1): 310-335.
10	徐小元，丁惠国，贾继东, 等. 肝硬化门静脉高压食管胃静脉曲张出血的防治指南 [J]. 实用肝脏病杂志, 2016, 19(5): 641-656.
11	Dohlman HG, Caron MG, Lefkowitz RJ. A family of receptors coupled to guanine nucleotide regulatory proteins [J]. Biochemistry, 1987, 26(10): 2657-2664.
12	Ahlquist RP. A study of the adrenotropic receptors [J]. Am J Physiol, 1948, 153(3): 586-600.
13	Langer SZ. Presynaptic regulation of catecholamine release [J]. Biochem Pharmacol, 1974, 23(13): 1793-1800.
14	Ruffolo RR, Hieble JP. Alpha-adrenoceptors [J]. Pharmacol Ther, 1994, 61(1/2): 1-64.
15	Civantos Calzada B, Aleixandre de Artiñano A. Alpha-adrenoceptor subtypes [J]. Pharmacol Res, 2001, 44(3): 195-208.
16	Docherty JR. The pharmacology of α1-adrenoceptor subtypes [J]. Eur J Pharmacol, 2019, 855: 305-320.
17	Penenberg D, Chung M, Walmsley P, et al. The effects of hepatic impairment on the pharmacokinetics of doxazosin [J]. J Clin Pharmacol, 2000, 40(1): 67-73.
18	Albillos A, Lledó JL, Rossi I, et al. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function [J]. Gastroenterology, 1995, 109(4): 1257-1265.
19	Dubuisson L, Desmoulière A, Decourt B, et al. Inhibition of rat liver fibrogenesis through noradrenergic antagonism [J]. Hepatology, 2002, 35(2): 325-331.
20	Hamasaki K, Nakashima M, Naito S, et al. The sympathetic nervous system promotes carbon tetrachloride-induced liver cirrhosis in rats by suppressing apoptosis and enhancing the growth kinetics of regenerating hepatocytes [J]. J Gastroenterol, 2001, 36(2): 111-120.
1	García-Sáinz JA, Vázquez-Prado J, del Carmen Medina L. Alpha 1-adrenoceptors: function and phosphorylation [J]. Eur J Pharmacol, 2000, 389(1): 1-12.
2	Püschel GP. Control of hepatocyte metabolism by sympathetic and parasympathetic hepatic nerves [J]. Anat Rec A Discov Mol Cell Evol Biol, 2004, 280(1): 854-867.
3	刘丽艳，刘若凡，黄宁, 等. alpha2B肾上腺素受体选择性化合物作用机制研究 [J]. 四川生理科学杂志, 2019, 41(4): 260-264.
21	Recknagel RO, Glende EA Jr, Dolak JA, et al. Mechanisms of carbon tetrachloride toxicity [J]. Pharmacol Ther, 1989, 43(1): 139-154.
22	Yoshiji H, Kuriyama S, Miyamoto Y, et al. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model [J]. Hepatology, 2000, 32(6): 1248-1254.
23	Benyon RC, Iredale JP, Goddard S, et al. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver [J]. Gastroenterology, 1996, 110(3): 821-831.
24	Iredale JP, Benyon RC, Arthur MJ, et al. Tissue inhibitor of metalloproteinase-1 messenger RNA expression is enhanced relative to interstitial collagenase messenger RNA in experimental liver injury and fibrosis [J]. Hepatology, 1996, 24(1): 176-184.
25	Muñoz-Ortega MH, Llamas-Ramírez RW, Romero-Delgadillo NI, et al. Doxazosin Treatment Attenuates Carbon Tetrachloride-Induced Liver Fibrosis in Hamsters through a Decrease in Transforming Growth Factor β Secretion [J]. Gut Liver, 2016, 10(1): 101-108.
26	Oben JA, Yang S, Lin H, et al. Norepinephrine and neuropeptide Y promote proliferation and collagen gene expression of hepatic myofibroblastic stellate cells [J]. Biochem Biophys Res Commun, 2003, 302(4): 685-690.
27	Oben JA, Roskams T, Yang S, et al. Hepatic fibrogenesis requires sympathetic neurotransmitters [J]. Gut, 2004, 53(3): 438-445.
28	Sancho-Bru P, Bataller R, Colmenero J, et al. Norepinephrine induces calcium spikes and proinflammatory actions in human hepatic stellate cells [J]. Am J Physiol Gastrointest Liver Physiol, 2006, 291(5): G877-G884.
29	Bioulac-Sage P, Lafon ME, Saric J, et al. Nerves and perisinusoidal cells in human liver [J]. J Hepatol, 1990, 10(1): 105-112.
30	Hsu CT. The role of the sympathetic nervous system in promoting liver cirrhosis induced by carbon tetrachloride, using the essential hypertensive animal (SHR) [J]. J Auton Nerv Syst, 1992, 37(3): 163-173.
31	Fukuda Y, Imoto M, Koyama Y, et al. Demonstration of noradrenaline-immunoreactive nerve fibres in the liver [J]. J Int Med Res, 1996, 24(6): 466-472.
32	Simonetto DA, Liu M, Kamath PS. Portal Hypertension and Related Complications: Diagnosis and Management [J]. Mayo Clin Proc, 2019, 94(4): 714-726.
33	Lenzen R, Funk A, Kolb-Bachofen V, et al. Norepinephrine-induced cholestasis in the isolated perfused rat liver is secondary to its hemodynamic effects [J]. Hepatology, 1990, 12(2): 314-321.
34	Rosmorduc O, Wendum D, Corpechot C, et al. Hepatocellular hypoxia-induced vascular endothelial growth factor expression and angiogenesis in experimental biliary cirrhosis [J]. Am J Pathol, 1999, 155(4): 1065-1073.
35	Lee WC, Lin HC, Yang YY, et al. Hemodynamic effects of a combination of prazosin and terlipressin in patients with viral cirrhosis [J]. Am J Gastroenterol, 2001, 96(4): 1210-1216.
36	Miñano C, Garcia-Tsao G. Clinical pharmacology of portal hypertension [J]. Gastroenterol Clin North Am, 2010, 39(3): 681-695.
37	修爱媛，王思宁，丁茜, 等. α₁肾上腺素受体阻滞剂降低肝硬化门静脉高压的实验研究 [J/OL]. 中华消化病与影像杂志(电子版), 2021, 11(3): 117-120.
38	Wu Y, Li Z, Xiu AY, et al. Carvedilol attenuates carbon tetrachlorideinduced liver fibrosis and hepatic sinusoidal capillarization in mice [J]. Drug Des Devel Ther, 2019, 13: 2667-2676.
39	Abraldes JG, Trebicka J, Chalasani N, et al. Prioritization of Therapeutic Targets and Trial Design in Cirrhotic Portal Hypertension [J]. Hepatology, 2019, 69(3): 1287-1299.
40	Kockerling D, Nathwani R, Forlano R, et al. Current and future pharmacological therapies for managing cirrhosis and its complications [J]. World J Gastroenterol, 2019, 25(8): 888-908.

[1]	Fangyuan Wu, Xia Sun, Changfeng Lin, Zhensheng Zhang. Risk factors of HBV-associated cirrhosis complicated with acute upper gastrointestinal bleeding [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 45-47.
[2]	Jianmei Li, Jingjuan Deng, Qian Yang. Safety and follow-up evaluation of the combined treatment of hepatocellular carcinoma with hepatic cirrhosis and portal hypertension [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2024, 18(01): 41-44.
[3]	Xian Mo, Chuang Yang. Meta-analysis of risk factors for portal vein thrombosis in patients with cirrhosis [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(06): 678-683.
[4]	Zhida Geng, Xingxin Yu, Yu Liu, Yingjian Liang. Research progress on portal vein system thrombosis and its mechanism after splenectomy [J]. Chinese Journal of Operative Procedures of General Surgery(Electronic Edition), 2023, 17(01): 110-113.
[5]	Xuexue Lei, Ying Yu, Hongyan Li. Clinical research of multimodal prehabilitation optimization program in patients with hepatitis B virus-related liver cirrhosis awaiting liver transplantation [J]. Chinese Journal of Transplantation(Electronic Edition), 2023, 17(03): 158-163.
[6]	Lina Wu, Lin Wei, Zhigui Zeng, Liang Zhang, Enhui He, Yule Tan, Zhijun Zhu, Liying Sun. Pulmonary arterial hypertension targeted drugs combined with liver transplantation for severe portalpulmonary hypertension: a case report [J]. Chinese Journal of Transplantation(Electronic Edition), 2022, 16(06): 376-378.
[7]	Xiaobei Zhang, Dong Cao, Baoshun Yang, Yongjiang Yu. Progress in the clinical management of cirrhotic ascites combined with inguinal hernia [J]. Chinese Journal of Hernia and Abdominal Wall Surgery(Electronic Edition), 2023, 17(02): 121-124.
[8]	Yuyang Xu, Yunfu Lyu, Baochun Wang. Progress of surgical treatments for splenomegaly in patients with hepatitis B cirrhotic portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 469-473.
[9]	Yong Li, Chuan Lan, Bin Wu, Guangnian Zhang, Jingdong Li. Predictive value of preoperative platelet-albumin score for postoperative prognosis of cirrhotic hepatocellular carcinoma patients [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(04): 412-416.
[10]	Linqing Yang, Song Ren, Fanpu Ji, Jian Zhang, An Jiang, Li Zhang, Peng An, Lin Wang, Zongfang Li. Therapeutic effect of needle-embedding therapy on regulating gastrointestinal function after splenectomy and devascularization for portal hypertension [J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2023, 12(03): 322-326.
[11]	Wei Qin, Dan Wang, Yu Sun, Yuling Huo, Suping Zhu, Yanli Zheng, Rui Xue. Predictive value of serum laminin and typeⅣcollagen on liver cirrhosis with ophageal and gastric varices bleeding [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 447-451.
[12]	Wen Zhang, Mudan Song, Xueting Deng, Yun Zhang. Enhanced nutritional support assisted with octreotide in the treatment of esophageal and gastric variceal bleeding in patients with liver cirrhosis and risk factors for rebleeding [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 456-460.
[13]	Xiangyu Zhu, Jianmei Wang, Hui Zhang, Hongying Ye. Correlation analysis between left ventricular function parameters and liver cirrhosis using non-invasive left ventricular pressure-strain cycle [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 494-498.
[14]	Fengshang Zhu, Ling She, Yongnian Ding, Changqing Yang. Application of the five-step questioning method in clinical teaching of cirrhotic portal hypertension [J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(02): 116-118.
[15]	Huiping Wei, Yingming Guo, Guirong Liu, Zongyou Wu, Qiuqing Weng. Application value of superoxide dismutase test in hepatitis B virus related liver disease [J]. Chinese Journal of Clinical Laboratory Management(Electronic Edition), 2023, 11(01): 21-26.

Please choose a citation manager

Content to export

Research progress of α₁ adrenergic receptor blockers in the treatment of liver cirrhosis

RichHTML

PDF (PC)

Knowledge

Cited

Abstract

Cite this article

share this article

References 40

Related Articles 15

Recommended Articles

Metrics

Comments

模态框（Modal）标题

Please choose a citation manager

Content to export